Idt Australia Limited · ASX:IDT
Idt Australia — Shareholder Meeting (October 2009)
15 slides from Idt Australia's shareholder meeting presentation, Oct 30, 2009
Slide 1: IDT 2009 AGM Presentation
IDT 2009 AGM For personal use only Presentation Dr Robyn Elliott Managing Director
Slide 2: IDT Business Areas
IDT Business Areas For personal use only • Contract Manufacturing: ¾ API Commercial Manufacturing ¾ Finished Dosage Form Commercial Manufacturing • Contract Development: ¾ R&D for new drugs - API and Finished Dosage Forms ¾ Phase I- Phase II clinical trials through CMAX
Slide 3: 2008/2009 Highlights
2008/2009 Highlights For personal use only • The successful completion of the Pfizer 4000L facility and the manufacture of the required antibiotic drug. • IDT achieved its first Paragraph IV “first to file” generic drug submission to the FDA . • IDT undertook validation programs required to enable o
Slide 4: IDT Objective
IDT Objective For personal use only Through technology excellence, responsible business practices and effective partnerships, the IDT team will provide a sustainable business profit growth and a shareholders return on investment which reflects outstanding performance.
Slide 5: Underlying Medium Term Outsourcing Growth
Underlying Medium Term For personal use only Outsourcing Growth • Drivers: – Large Pharma are closing plants and focusing on R&D/Marketing/Sales. – Biotech companies have ongoing clinical programs- few have in-house development/manufacturing capabilities. – Continued growth is observed in cancer the
Slide 6: Global Financial Crisis: Short Term Impact
Global Financial Crisis: Short Term For personal use only Impact • From November, 2008 – Large Pharma are closing plants, reviewing portfolios and consolidating R&D – Biotech companies have an ongoing difficulty in raising capital leading to a focus on reduced spending – Delays are evident in Phase
Slide 7: Other Issues
For personal use only Other Issues • Drivers: – The FDA is increasing the difficulty of drug registration leading to clinical delays – The high Australian dollar is affecting short term competitiveness – An increase in global plant and development service availability is leading to a short term decr
Slide 8: IDT Solutions
For personal use only • IDT Solutions – Global Business Development Focus – New Alliances/Clients – New Facility Focus – New Product/Market Focus – New Cost Saving focus
Slide 9: Global Focus
Global Focus For personal use only • Representation – Strengthened IDT’s relationship with: • the manufacturing representative company, Hampton Pharma, which has offices in East Coast and West Coast USA, and India. • The manufacturing representative company, Midas Pharma, with offices throughout Eur
Slide 10: IDT Facilities
IDT Facilities For personal use only Current API Facilities ¾ 250 Litre ¾ 400 Litre (x2) ¾ 100 Litre (x2) ¾ 60 Litre ¾ 20-50 Litre (x4) ¾ 2000 Litre Current Finished Product Facilities 9 Containment Tablet facility 9 Containment Capsule Facility 9 Thalidomide Capsule Facility 9 Clinical Packaging Fa
Slide 11: Pfizer Facilities
Pfizer Facilities • New facilities and equipment For personal use only were required to undertake the Pfizer contracts Sterile Facility Tablet Facility 4000L API Facility • The capital cost of these facilities was funded by Pfizer • Negotiations are on-going regarding the future ownership of the fac
Slide 12: Opportunities
Opportunities For personal use only • One of the few penem contract facilities in the world • Can offer API or Finished product development and manufacturing – (Tablets, Injection) • Upon successful completion of Pfizer negotiations, IDT will be able to market the availability of the Penem facility
Slide 13: IDT Cost Savings
IDT Cost Savings For personal use only IDT has proactively implemented cost saving measures including: Resource Restructuring Leave Utilization Key Supplier contract reviews Tighter internal authorisation levels Disbursement of costs to clients
Slide 14: Future Outcomes
Future Outcomes For personal use only 9 IDT has development contracts which offer long term commercial opportunities 9 IDT is in negotiation to enable use of the Pfizer facility into the future 9 IDT has opportunities for the development and manufacturing of new products and new markets 9 IDT has se
Slide 15: IDT Australia Limited
IDT Australia Limited For personal use only Tel: +61-3-9801-8888 Fax: +61-3-9801-8773 E-mail: relliott@idtaus.com.au